|
1
|
Ostrom QT, Gittleman H, Fulop J, Liu M,
Blanda R, Kromer C, Wolinsky Y, Kruchko C and Barnholtz-Sloan JS:
CBTRUS Statistical Report: Primary brain and central nervous system
tumors diagnosed in the united states in 2008–2012. Neuro Oncol. 17
Suppl 4:iv1–iv62. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zouaoui S, Rigau V, Mathieu-Daudé H,
Darlix A, Bessaoud F, Fabbro-Peray P, Bauchet F, Kerr C, Fabbro M,
Figarella-Branger D, et al: French brain tumor database: General
results on 40,000 cases, main current applications and future
prospects. Neurochirurgie. 58:4–13. 2012.(In French). View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Baldi I, Huchet A, Bauchet L and Loiseau
H: Epidemiology of glioblastoma. Neurochirurgie. 56:433–440.
2010.(In French). View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chakrabarti I, Cockburn M, Cozen W, Wang
YP and Preston-Martin S: A population-based description of
glioblastoma multiforme in Los Angeles County, 1974–1999. Cancer.
104:2798–2806. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Stupp R, Mason WP, van den Bent MJ, Weller
M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn
U, et al: Radiotherapy plus concomitant and adjuvant temozolomide
for glioblastoma. N Engl J Med. 352:987–996. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hart MG, Grant R, Garside R, Rogers G,
Somerville M and Stein K: Chemotherapy wafers for high grade
glioma. Cochrane Database Syst Rev. 16:CD0072942011.
|
|
7
|
Lonjon N, Bauchet L, Duffau H,
Fabbro-Peray P, Segnarbieux F, Paquis P and Lonjon M: Second
surgery for glioblastoma. A 4-year retrospective study conducted in
both the Montpellier and Nice Departments of Neurosurgery. A
literature review. Neurochirurgie. 56:36–42. 2010.
|
|
8
|
Addeo R, Caraglia M, De Santi MS, Montella
L, Abbruzzese A, Parlato C, Vincenzi B, Carraturo M, Faiola V,
Genovese M, et al: A new schedule of fotemustine in
temozolomide-pretreated patients with relapsing glioblastoma. J
Neurooncol. 102:417–424. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Levin VA, Wara WM, Davis RL, Vestnys P,
Resser KJ, Yatsko K, Nutik S, Gutin PH and Wilson CB: Phase III
comparison of BCNU and the combination of procarbazine, CCNU, and
vincristine administered after radiotherapy with hydroxyurea for
malignant gliomas. J Neurosurg. 63:218–223. 1985. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Cloughesy TF, Filka E, Kuhn J, Nelson G,
Kabbinavar F, Friedman H, Miller LL and Elfring GL: Two studies
evaluating irinotecan treatment for recurrent malignant glioma
using an every-3-week regimen. Cancer. 97(9 Suppl): S2381–S2386.
2003. View Article : Google Scholar
|
|
11
|
Prados MD, Lamborn K, Yung WK, Jaeckle K,
Robins HI, Mehta M, Fine HA, Wen PY, Cloughesy T, Chang S, et al: A
phase 2 trial of irinotecan (CPT-11) in patients with recurrent
malignant glioma: A north american brain tumor consortium study.
Neuro-Oncol. 8:189–193. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Quinn JA, Jiang SX, Reardon DA, Desjardins
A, Vredenburgh JJ, Rich JN, Gururangan S, Friedman AH, Bigner DD,
Sampson JH, et al: Phase II trial of temozolomide plus
o6-benzylguanine in adults with recurrent, temozolomide-resistant
malignant glioma. J Clin Oncol. 27:1262–1267. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Friedman HS, Prados MD, Wen PY, Mikkelsen
T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen
R, et al: Bevacizumab alone and in combination with irinotecan in
recurrent glioblastoma. J Clin Oncol. 27:4733–4740. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Vredenburgh JJ, Desjardins A, Herndon JE
II, Marcello J, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S,
Gururangan S, Sampson J, et al: Bevacizumab plus irinotecan in
recurrent glioblastoma multiforme. J Clin Oncol. 25:4722–4729.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Combs SE, Thilmann C, Edler L, Debus J and
Schulz-Ertner D: Efficacy of fractionated stereotactic
reirradiation in recurrent gliomas: Long-term results in 172
patients treated in a single institution. J Clin Oncol.
23:8863–8869. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Fogh SE, Andrews DW, Glass J, Curran W,
Glass C, Champ C, Evans JJ, Hyslop T, Pequignot E, Downes B, et al:
Hypofractionated stereotactic radiation therapy: An effective
therapy for recurrent high-grade gliomas. J Clin Oncol.
28:3048–3053. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Patel M, Siddiqui F, Jin JY, Mikkelsen T,
Rosenblum M, Movsas B and Ryu S: Salvage reirradiation for
recurrent glioblastoma with radiosurgery: Radiographic response and
improved survival. J Neurooncol. 92:185–191. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Derouesne C, Poitreneau J, Hugonot L,
Kalafat M, Dubois B and Laurent B: Mini-Mental State Examination: A
useful method for the evaluation of the cognitive status of
patients by the clinician. Presse Med. 28:1141–1148.
1999.PubMed/NCBI
|
|
19
|
Viel E, Chaigneau L, Fanton E, Kalbacher
E, Thiery-Vuillemnin A, Villanueva C, Dobi E, Curtit E, Almotlak H,
Aubry R and Pivot X: Specific anticancer treatments in the last 3
months of life: A French experience. Support Care Cancer.
21:405–412. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Earle CC, Neville BA, Landrum MB, Ayanian
JZ, Block SD and Weeks JC: Trends in the aggressiveness of cancer
care near the end of life. J Clin Oncol. 22:315–321. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Earle CC, Landrum MB, Souza JM, Neville
BA, Weeks JC and Ayanian JZ: Aggressiveness of cancer care near the
end of life: Is it a quality-of-care issue? J Clin Oncol.
26:3860–3866. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Emanuel EJ, Young-Xu Y, Levinsky NG,
Gazelle G, Saynina O and Ash AS: Chemotherapy use among medicare
beneficiaries at the end of life. Ann Intern Med. 138:639–643.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Barnato AE, Herndon MB, Anthony DL,
Gallagher PM, Skinner JS, Bynum JP and Fisher ES: Are regional
variations in end-of-life care intensity explained by patient
preferences? A Study of the US Medicare Population. Med Care.
45:386–393. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Voogt E, van der Heide A, Rietjens JA, van
Leeuwen AF, Visser AP, van der Rijt CC and van der Maas PJ:
Attitudes of patients with incurable cancer toward medical
treatment in the last phase of life. J Clin Oncol. 23:2012–2019.
2005. View Article : Google Scholar : PubMed/NCBI
|
